维普期刊资源整合服务平台（V6.5）

57篇 您的检索式：作者名="Kreisl"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	Investigation of tumor angiogenesis in an id mouse model: role of host-tumor intevaitions 显示文摘	Kreisle RA Ershler WB	1988	J Natl Cancer Inst1988，80，11：	2
2	Ischemic stroke in patients with primary brain tumors显示文摘	Kreisl TN Toothaker T Karimi S		0，，24：	1
3	Phase II trial of single- agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma 显示文摘	Kreisl TN Kim L Moore K	2009	J Clin Oncol2009，27，5：	1
4	Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma 显示文摘	Kreisl TN Kim L Moore K	2009	J Clin Oncol2009，27，5：	1
5	Continuous daily sunitinib for recurrent glioblastoma显示文摘	Kreisl TN Smith P Sul J	2013	J Neurooncol2013，111，：	1
6	Detection of Fcgamma receptors on human endothelial cells stimulated with cytokines tumour necrosis factor - alpha ( TNF - alpha) and interferon-gamma ( IFN - gamma) 显示文摘	Pan LF Kreisle RA Shi YD	1998	Clin Exp Immunol1998，112，3：	1
7	At-03 phase I trial of enzastaurin (ly317615) in combination with carboplatin in adults with recurrent giioma 显示文摘	Ambady P Kreisl T Warren K	2014	Neuro Oncol2014，16，5：	1
8	Phase II trial of single-agent bevacizumab followed by bevacizumab plus iri-notecan at tumor progression in recurrent glioblastoma显示文摘	Kreisl TN Kim L Moore K		0，，05：	1
9	Phase II trial of singleagent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma显示文摘	Kreisl TN Kim L Moore K	2009	J Clin Oncol2009，27，：	1
10	Phase II trial of single-agentbevacizumab followed by bevacizumab plus irinotecan at tumorprogression in recurrent glioblastoma显示文摘	Kreisl TN Kim L Moore K	2009	J Clin Oncol2009，27，5：	1
11	Investigation of tumor angioge-Nesis in an idmouse model:role of host-tumor intevaitions J显示文摘	Kreisle RA Ersh lerWB	1988	J Natl Cancer Inst1988，80，11：	1
12	Molecular cloning of a novel phytochrome gene of the moss Ceratodon purpureus which encodes a putative light-regulated protein kinase显示文摘	Thummler F Dufner M Kreisl P	1992	Plant Molecular Biology1992，20，6：	1
13	Phase II trial of single- agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma显示文摘	Kreisl TN Kim L Moore K	2009	J Clin Oncol2009，27，5：	1
14	Micromechanical Fabrication of Robust, Low-Power Metal-Oxide Gas Sensors 显示文摘	Friedberger A Kreisl P Rose E	2003	Sensors & Actuators2003，93，2：	1
15	In rive and in vitro characteristics of interleukin-6 transfected B16 melanoma cell 显示文摘	Sun WH Kreisle RA Kischer CW	1992	Cancer Res1992，53，：	1
16	Phase Ⅱ trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma 显示文摘	Kreisl TN Kim L Moore K	2009	J Clin Oncol2009，27，5：	1
17	Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma 显示文摘	Kreisl TN Kim L Moore K	2009	J Clin Oncol2009，27，：	1
18	Lymphocyte-induced angiogenesis factor is produced by L3T4+ murine T lymphocytes, and its production declines with age显示文摘	Eldad J. Hadar William B. Ershler Regina A. Kreisle Shu-Peng Ho Michael J. Volk Roger G. Klopp	1988	Cancer Immunology Immunotherapy1988，，1：	1
19	Investigation of tumor angiogenesis in an id mouse model: role of host-tumor intevaitions显示文摘	Kreisle RA Ershler WB	1988	J Natl Cancer Inst1988，80，11：	1
20	Neuromuscular junction toxiei- ty with tandutinib induces a myasthenic - like syndrome 显示文摘	Lehky TJ Iwamoto FM Kreisl TN	2011	Neurolo- gy2011，76，3：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示